Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Teijin
Teijin
Activities:
Cardiovascular
Bone & Joint Health
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
N4 Pharma and SRI to target and treat previously unreachable human cells
The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec to increase intracellular delivery to specific target cells.
Berry Global invests to increase production capacity for healthcare products
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Teijin and Axcelead to determine the name of drug discovery research venture
Axcelead TWP’s business will include supporting drug discovery-related activities from target selection to the discovery of candidate compounds and related research activities
Manufacturing
Teijin Frontier introduces new nonwoven microcarriers for speedy and large-scale cell culture
The new nonwoven microcarriers combine Teijin Frontier’s proprietary fibre process and nonwoven design technology and fibre-related bio-medical expertise by Professor Satoshi Fujita
Manufacturing
Teijin enters LoI for cell and gene therapies
The development of preferred clinical trial and regulatory pathways for the companies’ customers is also under discussion
Drug Delivery
Teijin and Axcelead's agreement on capital and business alliance
The new company will utilise Teijin's drug discovery research technologies, facilities, equipment and personnel
Research & Development
Teijin, J-TEC, Mitsui Fudosan and NCC establish regenerative medicine platform
The platform supports the development of innovative treatments for diseases with unmet needs such as cancer
Finance
Teijin Pharma and TransThera form strategic R&D collaboration
The two companies say they’re confident they can complement their respective strengths in small molecule drug discovery
Research & Development
Teijin signs agreement to research drugs for frailty in elderly people
Japanese pharma company eyes a gap in the market that will become increasingly imperative with the rising longevity in Japan
Subscribe now